Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)

NCT02566993 is registered in ClinicalTrials.gov with PharmaMar as lead sponsor.

NCT NCT02566993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02566993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus Cyclophosphamide, Doxorubicin and Vincristine (CAV) or Topotecan as Treatment in Patients With Small-Cell Lung Cancer (SCLC) Who Failed One Prior Platinum-containing Line (ATLANTIS)
Lead sponsor
PharmaMar
Phase
Phase 3
Overall status
Completed
Start date
August 30, 2016
Completion date
February 24, 2020
Enrollment
613 (actual)
Sites
160

Conditions

As the registry lists them; a condition with its own page is linked.

small-cell lung cancer